Neutralizing antibodies
The Problem HCV is a major public health problem, with over 185 million people infected worldwide and at risk for developing life-threatening liver disease. Although FDA approved several Direct-Acting Antiviral Drugs (DAAs) demonstrating high efficacy and safety, they are highly expensive and unaffordable. Vaccines typically represent the most cost-effective strategy to prevent infectious disease which…
Read More
Recent Comments